• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>International Gastric Cancer Congress >Clinical Trial of Liposome-Adriamycin (Lipo-ADR) via the Portal Vein and Hepatic Artery for Prophylaxis and Treatment after Hepatic Resection on Liver Metastasis in Advanced Gastric Cancer
【24h】

Clinical Trial of Liposome-Adriamycin (Lipo-ADR) via the Portal Vein and Hepatic Artery for Prophylaxis and Treatment after Hepatic Resection on Liver Metastasis in Advanced Gastric Cancer

机译：脂质体 - 阿霉素（Lipo-ADR）通过门静脉和肝动脉进行预防和治疗治疗晚期胃癌肝转移后的临床试验

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purposes we have studied the effects of liposome-adriamycin(Lipo-ADR) administered via the portal vein and hepatic artery experimentally. The liver concentration of ADR to the metastatic foci increased after delivery and cardiac uptake decreased compared with free ADR. We initiated the clinical application after hepatic resection. Materials and Methods To date of the December 2007, 12 patients (pts) (with continual locoregional chemotherapy for inoperable liver metastasis), At the same time, 18 pts (without locoregional chemotherapy for inoperable liver metastasis), 16 pts (included 6 pts with Lipo-ADR) after hepatic resection were enrolled in this study. Results The survival time(ST) of 12 pts was prolonged compared to 18 pts (P=0.047). The MST of 16 pts was 22.5 months. Furthermore, the MST of 6 pts with Lipo-ADR significantly prolonged compared to 10 pts without Lipo-ADR. (p=0.004) Conclusions These results suggested that chemotherapy with Lipo-ADR probably inhibits remnant liver metastases and prolongs the ST.
机译：目的我们研究了通过实验通过门静脉和肝动脉施用的脂质体 - 阿霉素（LIPO-ADR）的影响。与游离ADR相比，递送和心脏摄取后，ADR对转移性焦点的肝浓度增加。我们在肝切除后启动了临床应用。 2007年12月12月的材料和方法，12名患者（PTS）（具有持续的肝脏转移的营养型化疗），同时，18分（没有型肝脏转移的型患者化疗），16分（包括6分Lipo-ADR）肝切除术后纳入本研究。结果与18分（P = 0.047）相比，延长了12分的生存时间（ST）。 16分的MST为22.5个月。此外，在没有Lipo-ADR的情况下，脂肪-ADR的6分的6分的MST显着延长。 （p = 0.004）结论这些结果表明，使用Lipo-Adr的化疗可能抑制残余肝转移并延长ST。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号